Skip to content

US · KLRA · BIOTECHNOLOGY

Kailera Therapeutics, Inc. (KLRA) intrinsic value and stock valuation

$11.02as of 2026-11-21 · Mkt cap 2.35B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Kailera Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values KLRA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from KLRA’s statements →

Kailera Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Waltham, MA 02451 kailera.com

How the business is doing

Fiscal 2025–2025, USD

Revenue
$0.00
20252025
Net income
-$-148.96M
20252025
Free cash flow
-$-122.3M
20252025
Total equity
-$-356.46M
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2025, USD
2025
Revenue$0.00
Operating income-$-158.34M
Net income-$-148.96M
EPSd-$-1.26M
Operating cash flow-$-120.21M
Capital expenditure-$-2.09M
Free cash flow-$-122.3M
Total assets$692.3M
Total debt$10.8M
Net debt-$-149.51M
Total equity-$-356.46M
Cash and short-term investments$546.1M
Income statement
2025
Revenue$0.00
Cost of revenue$0.00
Gross profit$0.00
Research and development expenses$109.1M
Selling, general and administrative expenses$49.2M
Other expenses$0.00
Operating expenses$158.3M
Cost and expenses$158.3M
Interest income$11.1M
Interest expense$0.00
Depreciation and amortization$310K
Ebitda-$-158.03M
Operating income-$-158.34M
Total other income/expenses, net$9.38M
Income before tax-$-148.96M
Income tax expense$0.00
Net income-$-148.96M
Weighted average shares outstanding$118M
Weighted average diluted shares outstanding$118M
Balance sheet
2025
Cash and short-term investments$546.1M
Net receivables$2.73M
Inventory$0.00
Total current assets$557.5M
Property, plant and equipment, net$12.4M
Goodwill and intangible assets$0.00
Long-term investments$106.7M
Total non-current assets$134.8M
Total assets$692.3M
Accounts payable$7.53M
Short-term debt$1.04M
Deferred revenue$0.00
Total current liabilities$46.4M
Long-term debt$9.71M
Deferred revenue, non-current$0.00
Total non-current liabilities$1B
Capital lease obligations$10.8M
Total liabilities$1.05B
Common stock$0.00
Retained earnings-$-368.67M
Accumulated other comprehensive income (loss)$230K
Total equity-$-356.46M
Total investments$492.5M
Total debt$10.8M
Net debt-$-149.51M
Cash flow statement
2025
Net income-$-148.96M
Depreciation and amortization$310K
Stock-based compensation$10.9M
Change in working capital$16.8M
Accounts receivable$0.00
Inventory$0.00
Accounts payable$4.69M
Net cash provided by operating activities-$-120.21M
Investments in property, plant and equipment-$-2.09M
Acquisitions, net$0.00
Net cash used for investing activities-$-492.6M
Common stock issued$499M
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities$598.7M
Net change in cash-$-14.15M
Cash at end of period$161M
Operating cash flow-$-120.21M
Capital expenditure-$-2.09M
Free cash flow-$-122.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Kailera Therapeutics, Inc.

        Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.

        CEO
        Ronald C. Renaud Jr.
        Employees
        145
        Beta
        0.50

        Explore

        Frequently asked questions

        What is the intrinsic value of Kailera Therapeutics, Inc. (KLRA)?

        InvestorsCraft does not currently publish an intrinsic value for KLRA. How the IC value is calculated.

        Is KLRA undervalued?

        InvestorsCraft does not publish an undervaluation signal for KLRA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.